Silexion Therapeutics Warrant
SLXNW
22 hedge funds and large institutions have $128K invested in Silexion Therapeutics Warrant in 2025 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
18% more capital invested
Capital invested by funds: $108K → $128K (+$19.9K)
0% more funds holding
Funds holding: 22 → 22 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
1.67% less ownership
Funds ownership: 44.83% → 43.16% (-1.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.42K |
| 2 |
OMC
Oasis Management Company
Grand Cayman,
Cayman Islands
|
+$390 |
| 3 |
Goldman Sachs
New York
|
+$108 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
Hartree Partners
New York
|
-$6.4K |
| 2 |
CS
Clear Street
New York
|
-$7 |
SLXNW Hedge Fund Activity: Q3 2025 in Review
22 of the 7,645 institutional investors tracked by Wall St. Rank reported a position in Silexion Therapeutics Warrant (SLXNW) for Q3 2025, worth a combined $128K — up 18% from $108K a quarter earlier.
Fund positioning in SLXNW was balanced in Q3 2025: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 1 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $2.42K. The largest seller was Hartree Partners, exiting entirely with an estimated $6.4K sold.
- 22 institutional investors held Silexion Therapeutics Warrant (SLXNW) as of Q3 2025, unchanged from Q2 2025.
- Funds reported $128K of Silexion Therapeutics Warrant stock for Q3 2025, up 18% quarter-over-quarter.
- 1 fund opened new Silexion Therapeutics Warrant positions in Q3 2025 and 1 closed out, a net change of 0 holders.
- The largest Silexion Therapeutics Warrant buyer in Q3 2025 was Susquehanna International Group, an estimated $2.42K added.
- The largest Silexion Therapeutics Warrant seller in Q3 2025 was Hartree Partners, an estimated $6.4K sold.
Based on aggregated 13F filings for Q3 2025.